Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Completed Phase 4 Interventional Results available

Efficacy and Safety of Alirocumab Versus Usual Care on Top of Maximally Tolerated Statin Therapy in Patients With Type 2 Diabetes and Mixed Dyslipidemia (ODYSSEY DM-Dyslipidemia)

ClinicalTrials.gov ID: NCT02642159

Public ClinicalTrials.gov record NCT02642159. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced May 8, 2026, 2:55 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Randomized, Open-Label, Parallel Group Study to Evaluate the Efficacy and Safety of Alirocumab Versus Usual Care in Patients With Type 2 Diabetes and Mixed Dyslipidemia at High Cardiovascular Risk With Non-HDL-C Not Adequately Controlled With Maximally Tolerated Statin Therapy

Study identification

NCT ID
NCT02642159
Recruitment status
Completed
Study type
Interventional
Phase
Phase 4
Lead sponsor
Sanofi
Industry
Enrollment
413 participants

Conditions and interventions

Conditions

Interventions

  • Alirocumab Drug
  • Antihyperglycemic Drug Drug
  • Ezetimibe Drug
  • Fenofibrate Drug
  • Nicotinic acid Drug
  • Omega-3 fatty acids Drug
  • Statins Drug

Drug

Eligibility (public fields only)

Age range
18 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Mar 14, 2016
Primary completion
Mar 21, 2017
Completion
May 14, 2017
Last update posted
Apr 30, 2018

2016 – 2017

United States locations

U.S. sites
57
U.S. states
22
U.S. cities
54
Facility City State ZIP Site status
Investigational Site Number 840-163 Little Rock Arkansas 72205
Investigational Site Number 840-141 Fresno California 93720
Investigational Site Number 840-152 Huntington Beach California 92648
Investigational Site Number 840-115 La Jolla California 92037
Investigational Site Number 840-118 Los Angeles California 90057
Investigational Site Number 840-106 Northridge California 91325
Investigational Site Number 840-176 Port Hueneme California 93041
Investigational Site Number 840-122 Tarzana California 91356
Investigational Site Number 840-156 Tustin California 92780-6953
Investigational Site Number 840-160 Van Nuys California 91405
Investigational Site Number 840-107 Boca Raton Florida 33434
Investigational Site Number 840-170 Boynton Beach Florida 33472
Investigational Site Number 840-114 Bradenton Florida 34201
Investigational Site Number 840-132 Ocoee Florida 34761
Investigational Site Number 840-179 Oviedo Florida 32765
Investigational Site Number 840-123 Tampa Florida 33634
Investigational Site Number 840-137 Bainbridge Georgia 39819
Investigational Site Number 840-128 Columbus Georgia 31904
Investigational Site Number 840-169 Stockbridge Georgia 30281
Investigational Site Number 840-167 Idaho Falls Idaho 83404
Investigational Site Number 840-161 Chicago Illinois 60607
Investigational Site Number 840-184 Crystal Lake Illinois 60012
Investigational Site Number 840-174 Evanston Illinois 60201
Investigational Site Number 840-138 Springfield Illinois 62711
Investigational Site Number 840-108 Louisville Kentucky
Investigational Site Number 840-183 Paducah Kentucky 42003
Investigational Site Number 840-190 Metairie Louisiana 70006
Investigational Site Number 840-151 Rockville Maryland 20852
Investigational Site Number 840-113 Jefferson City Missouri 65109
Investigational Site Number 840-120 St Louis Missouri 63110
Investigational Site Number 840-148 Omaha Nebraska 68131-2137
Investigational Site Number 840-101 Las Vegas Nevada 89119
Investigational Site Number 840-140 Las Vegas Nevada 89128
Investigational Site Number 840-178 Albany New York 12206
Investigational Site Number 840-181 New York New York 10016
Investigational Site Number 840-157 New York New York 10029
Investigational Site Number 840-188 Greensboro North Carolina 27408
Investigational Site Number 840-131 Morehead City North Carolina 28557
Investigational Site Number 840-158 Morganton North Carolina 28655
Investigational Site Number 840-129 Fargo North Dakota 58103
Investigational Site Number 840-104 Columbus Ohio 43213
Investigational Site Number 840-105 Marion Ohio 43302
Investigational Site Number 840-175 Maumee Ohio 43537
Investigational Site Number 840-136 Bend Oregon 97702
Investigational Site Number 840-187 Murrells Inlet South Carolina 29576-9351
Investigational Site Number 840-111 Summerville South Carolina 29485
Investigational Site Number 840-147 Chattanooga Tennessee 37404
Investigational Site Number 840-159 Knoxville Tennessee 37920
Investigational Site Number 840-153 Dallas Texas 75230
Investigational Site Number 840-143 Houston Texas 77095
Investigational Site Number 840-168 Houston Texas 77099
Investigational Site Number 840-142 Round Rock Texas 78681
Investigational Site Number 840-133 Tomball Texas 77375
Investigational Site Number 840-185 Orem Utah 84058
Investigational Site Number 840-150 Salt Lake City Utah 84102
Investigational Site Number 840-126 Chesapeake Virginia 23321
Investigational Site Number 840-171 Richmond Virginia 23249

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 62 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT02642159, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Apr 30, 2018 · Synced May 8, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT02642159 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →